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Introduction: Myasthenia gravis is an autoimmune disease characterized by fluctuating muscle weakness. It is often
associated with other autoimmune disorders, such as thyroid disease, rheumatoid arthritis, systemic lupus
erythematosus, and antiphospholipid syndrome. Many aspects of autoimmune diseases are not completely
understood, particularly when they occur in association, which suggests a common pathogenetic mechanism.
Case presentation: We report a case of a 42-year-old Caucasian woman with antiphospholipid syndrome, in whom
myasthenia gravis developed years later. She tested negative for both antibodies against the acetylcholine receptor
and against muscle-specific receptor tyrosine-kinase, but had typical decremental responses at the repetitive nerve
stimulation testing, so that a generalized myasthenia gravis was diagnosed. Her thromboplastin time and activated
partial thromboplastin time were high, anticardiolipin and anti-β2 glycoprotein-I antibodies were slightly elevated,
as a manifestation of the antiphospholipid syndrome. She had a good clinical response when treated with a
combination of pyridostigmine, prednisone and azathioprine.
Conclusions: Many patients with myasthenia gravis test positive for a large variety of auto-antibodies, testifying
of an immune dysregulation, and some display mild T-cell lymphopenia associated with hypergammaglobulinemia and
B-cell hyper-reactivity. Both of these mechanisms could explain the occurrence of another autoimmune condition, such
as antiphospholipid syndrome, but further studies are necessary to shed light on this matter.
Clinicians should be aware that patients with an autoimmune diagnosis such as antiphospholipid syndrome who
develop signs and neurological symptoms suggestive of myasthenia gravis are at risk and should prompt an emergent
evaluation by a specialist.
Keywords: Antibodies against acetylcholine receptor, Antibodies against muscle-specific receptor tyrosine-kinase,
Antibodies against ryanodine receptor, Antibodies against titin, Antiphospholipid syndrome, Autoimmune disorders,
Seronegative myasthenia gravisIntroduction
The manifestations of myasthenia gravis (MG) are muscle
fatigability and weakness, caused by antibody-mediated re-
action against the nicotinic acetylcholine receptor (AChR)
at the neuromuscular junction [1,2]. Muscle-specific
receptor tyrosine-kinase (MuSK) is a protein associated
with the AChR, playing a role in its assembly [3]. The
antibodies (Ab) against AChR are mostly of immuno-
globulin G1 (IgG1) and IgG3 subclass; they induce a
reduction in the number of available AChR molecules* Correspondence: diana.dan@insel.ch
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reproduction in any medium, provided the orthrough cross-linking and accelerated degradation and
through complement-mediated destruction of the post-
synaptic membrane, resulting in a decrease of muscular
response. Unlike AChR-Ab, MuSK-Ab are predominantly
IgG4 and unable to activate complement, but they prob-
ably activate and internalize MuSK, which leads to a re-
duction and dispersal of AChR [4]. Results from several
electrophysiological studies suggest that MuSK-Ab dis-
turb both pre- and postsynaptic functions [5]. They in-
hibit muscle cell proliferation and downregulate the
expression of AChR. Other antibodies seen in MG are anti-
bodies against titin and ryanodine receptor. They bind to
skeletal and heart muscle and are found in up to 95% of
MG associated with thymoma and in 50% of late-onset
MG. Also, antibodies against lipoprotein receptor-related. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is not clear. Further structures of the neuromuscular junc-
tion, like agrin and ColQ (the collagen-tail subunit of
acetylcholinesterase) seem to act as autoantigens in MG,
but information about their pathogenic role is lacking [6].
The first clinical signs of MG are diplopia and eyelid ptosis,
defining the ocular form of the disease. In generalized
MG the weakness extends to bulbar muscles (dysarthria,
dysphonia, chewing and swallowing difficulties), trunk
(respiratory difficulties), and limbs.
The differential diagnosis includes, for the ocular form:
stroke, multiple sclerosis, thyroid ophthalmopathy, men-
ingitis and chronic progressive ophthalmoplegia; for the
generalized form: Lambert–Eaton syndrome, congenital
myasthenia, botulism, Guillain–Barré syndrome and amyo-
trophic lateral sclerosis.
Of the patients, 50 to 90% are AChR-Ab positive, with
the highest rate of “seropositivity” in the generalized
form [2]. MuSK-Ab are positive in 40% of the patients
who are AChR-Ab-negative with generalized form, and
usually negative in the ocular form. Patients who are
AChR-Ab-negative but MuSK-Ab-positive have more
predominantly bulbar involvement and more severe dis-
ease, with poorer response to therapy. This emphasizes
the predictive value of specific antibodies analysis in pa-
tients with MG [7]. After 12 months, 15% of the patients
who are initially seronegative for AChR-Ab will become
seropositive as recently shown by Chan et al. [8]. The
same authors found that among patients who are per-
sistently seronegative, 38% are MuSK antibody-positive,
and 43% are seropositive for miscellaneous, not muscle-
related antibodies.Table 1 Revised classification criteria for the antiphospholipid
Antiphospholipid syndrome is present if at least one of the clinical crit
CC1. Vascular thrombosis One or more clinical episode
CC2. Pregnancy morbidity a) One or more unexplained
gestation, with normal fetal m
fetus, or
b) One or more premature b
gestation because of: (i) ecla
insufficiency, or
c) Three or more unexplained
maternal anatomic or hormon
LC1. Lupus anticoagulant present in plasma on two or
LC2. Anticardiolipin antibody Of IgG and/or IgM isotype in
or > the 99th percentile), on t
LC3. Anti-β2 glycoprotein-I antibody Of IgG and/or IgM isotype in
at least 12 weeks apart
Abbreviations: CC, clinical criteria; Ig, immunoglobulin; GPL, IgG phospholipid units;
*Classification of antiphospholipid syndrome should be avoided if less than 12 wee
clinical manifestation.
**Thrombosis must be confirmed by objective validated criteria (that is, unequivoca
histopathologic confirmation, thrombosis should be present without significant evid
categories: I: more than one laboratory criterion present (any combination); IIa: lupu
anti-β2 glycoprotein-I antibody present alone.The thymus is involved in the pathogenesis of the dis-
ease, with abnormalities in 75% of cases, of which 85%
are thymic hyperplasia and 15% thymoma [9]. A com-
mon feature of the seronegative MG for AChR-Ab is the
low frequency of the thymic pathology [10,11].
MG may be associated with other autoimmune disor-
ders such as thyroiditis, vitiligo, rheumatoid arthritis,
connective tissue diseases or antiphospholipid syndrome
(APS) [1].
APS is a disorder that manifests clinically as recurrent
venous or arterial thrombosis and fetal loss. Laboratory
abnormalities include evidence of a circulating anticoagu-
lant or elevated levels of antibodies against membrane an-
ionic phospholipids or their associated plasma proteins.
Classification criteria are listed in Table 1 [12].
APS occurs alone or in association with systemic lupus
erythematosus or other rheumatic or autoimmune disor-
ders. Not all people with the above-mentioned anti-
bodies experience clinical complications, suggesting that
other factors related to antibody specificity or host sus-
ceptibility may play a role.
Case presentation
A 42-year-old Caucasian woman was admitted to our
hospital because of fluctuating diplopia, ptosis, dyspha-
gia, dysarthria and fatigable chewing at the end of meals
or at the end of the day. Also, she would not answer the
phone anymore because of her fear of not being able to
finish a conversation. Her medical history included APS
(that had led to three spontaneous abortions) and transi-
tory hypothyroidism. She took acetylsalicylic acid 81mg
daily.syndrome
eria and one of the laboratory criteria that follow are met*
s of arterial, venous, or small vessel thrombosis, in any tissue or organ**
deaths of a morphologically normal fetus at or beyond the 10th week of
orphology documented by ultrasound or by direct examination of the
irths of a morphologically normal neonate before the 34th week of
mpsia or severe preeclampsia, or (ii) recognized features of placental
consecutive spontaneous abortions before the 10th week of gestation, with
al abnormalities and paternal and maternal chromosomal causes excluded
more occasions at least 12 weeks apart
serum or plasma present in medium or high titer (i.e. >40GPL or MPL,
wo or more occasions at least 12 weeks apart
serum or plasma (in titer > the 99th percentile), on two or more occasions
LC, laboratory criteria; MPL, IgM phospholipid units.
ks or more than 5 years separate the positive antiphospholipid test and the
l findings of appropriate imaging studies or histopathology). For
ence of inflammation in the vessel wall. Antiphospholipid syndrome
s anticoagulant present alone; IIb: anticardiolipin antibody present alone; IIc:
Table 2 Laboratory findings in our patient
Parameters Units Normal
White blood cells 7.0 109/L 4.0–10.0
Red blood cells 131 109/L 117–157
Platelets 220 109/L 150–350
Erythrocyte sedimentation rate 32 mm/h <20
Thromboplastin time 80 % 85–125
Activated partial thromboplastin time 37 sec 21–33
Thyroid-stimulating hormone 2.95 mU/L 0.20–3.50
Myasthenia gravis antibodies
Anti-titin 0.6 Quot. <0.9
Anti-MuSK 0.01 nmol/L <0.05
Anti-AChR <0.02 pmol/L <0.02
Rheumatoid factor <11 UI/mL <20
Antinuclear antibodies 1:320, Positive homogenous <1:80
Anti-dsDNA antibodies 60 UI/mL <200
Anti-nucleoproteins antibodies 9 U <20
Antineutrophil cytoplasmic antibodies
cANCA Negative
pANCA Negative
Anticardiolipin antibodies
IgG, A, M (screening-test) 2.0 <1.0
IgG 21.0 GPL <15
IgM 27.0 MPL <12.5
Anti-β2 glycoprotein-I antibody
IgG, A, M (screening-test) 5.4 <1.0
IgG 48.0 GPL <20
IgM 53.0 MPL <20
Pathologic values in bold.
Abbreviations: AChR, acetylcholine receptor; ANCA, antineutrophil cytoplasmic antibodies; dsDNA, double-stranded DNA; h, hour; GPL, IgG phospholipid units; Ig,
immunoglobulin; MPL, IgM phospholipid units; MuSK, muscle-specific receptor tyrosine-kinase; Quot, Quotient; sec, seconds.
Table 3 Cases with myasthenia gravis associated with antiphospholipid syndrome
Case Manifestations of
myasthenia gravis
Manifestations of
antiphospholipid syndrome
Laboratory findings
Kaji et al. [13] Woman, 47 Began after thymectomy Prolonged aPTT, thrombocytopenia, anti-β2
glycoprotein-I antibody positive
Diplopia, weakness of arms and
legs with prolonged exertion
Phlebothrombosis of the lower extremity,
multiple strokes
Anti AChR-Ab 61nmol/L (N <0.2nmol/L)
Shoenfeld et al. [14] Woman, 32 Began after thymectomy Abortion, stroke
and spleen artery thrombosis
Anticardiolipin antibodies positive
Hand weakness Anti AChR-Ab positive
Watanabe et al. [15] Woman, 40 Diplopia,
bilateral ptosis
Abortion, pulmonary embolism Prolonged aPTT, thrombocytopenia, anti-β2
glycoprotein-I antibody and lupus
anticoagulant positive
Anti AChR-Ab 490nmol/L (N <0.2nmol/L)
Present case Woman, 42 Fluctuating
faciobulbar weakness
Abortions Prolonged aPTT, anti-β2 glycoprotein-I and
anticardiolipin antibody positive
Antinuclear-Ab positive
Anti AChR-Ab, MuSK-Ab, titin-Ab negative
Abbreviations: Ab, antibodies; AChR, acetylcholine receptor; APTT, activated partial thromboplastin time; MuSK, muscle-specific receptor tyrosine-kinase.
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facial muscles, tongue and neck. She displayed progressive
fatigability in upward gaze during the Simpson test. Repeti-
tive ulnar nerve stimulation showed abnormal (>10%) dec-
rement. The results of tests to detect antibodies against
AChR, MuSK and titin were negative. A generalized MG
was diagnosed. Her thoracic computed tomography scan
was normal. Thromboplastin time and activated partial
thromboplastin time were high, as an expression of the
APS; anticardiolipin and anti-β2 glycoprotein-I antibodies
were elevated. Laboratory findings are shown in Table 2.
She had a good clinical response when treated with
pyridostigmine, prednisone and azathioprine.
Discussion
A review of the literature suggests that there could be a
link between APS and MG, as both are autoimmune dis-
orders. Exceptional case reports with this particular clin-
ical association are listed in Table 3.
In two cases, APS became manifest years after a thym-
ectomy. Patients with MG who have been thymecto-
mized display over the years mild T-cell lymphopenia,
hypergammaglobulinemia and B-cell hyper-reactivity, most
probably related to the loss of suppressor T-cells. This
could lead to an associated autoimmune disease. However,
this explanation does not apply either for the third
or for our own case, APS having been diagnosed years
before MG.
Equally, many patients with MG test positive for a
large variety of autoantibodies, even in the absence
of thymectomy. In a serologic study, Sanmarco and
Bernard [16] found in 71 patients with MG a prevalence
of 25% of IgG-class anticardiolipin antibodies, and these
were significantly associated with thymic abnormalities
such as thymoma or thymic hyperplasia. This mechanism
could favor the emergence of other autoimmune diseases,
such as APS.
Conclusions
We have reported a case of MG in which an APS was di-
agnosed a few years before. The patient tested negative
for both AChR-Ab and MuSK-Ab, which is a very rare
situation. Recently published data have shown that
MuSK-positive and MuSK-negative MG are distinct clin-
ical entities, with a better prognosis for the AChR-positive
and MuSK-negative forms of the disease. This emphasizes
the predictive value of specific antibodies analysis in
patients with MG.
Very few other cases of concomitant MG and APS
have been described and this raises the hypothesis of
a continuum in certain autoimmune diseases. Little is
known about the causality and the pathogenicity of these
associated disorders. Contrary to our case, there might be
a relationship between thymectomy in MG and occurrenceof other autoimmune diseases such as APS but data are
scarce and subject to controversy. It is expected that other
mechanisms should be considered for explaining what
could trigger the development of concomitant dysimmune
response to different targets and this could probably be
studied by chromatin immunoprecipitation assay, a power-
ful tool to study protein–deoxyribonucleic acid (DNA)
interactions from different tissues.
Clinicians should be aware that patients with an auto-
immune diagnosis such as APS who develop signs and
neurological symptoms suggestive of MG are at risk and
should prompt an emergent evaluation by a specialist.
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